部份中文雷德帕斯处方资料(仅供参考) 英文商品:Rydapt 英文药名:midostaurin 中文药名:雷德帕斯 研发厂家名:Novartis 批准上市:2017年5月4日 剂型:胶囊 作用机制 Midostaurin是抑制多种受体酪氨酸激酶的小分子。 体外生物化学或细胞测定显示,midostaurin或其主要的人类活性代谢物CGP62221和CGP52421抑制野生型FLT3,FLT3突变型激酶(ITD和TKD),KIT(野生型和D816V突变体),PDGFRα/β,VEGFR2的活性 ,以及丝氨酸/苏氨酸激酶PKC(蛋白激酶C)家族的成员。 中度石蜡表现出抑制FLT3受体信号传导和细胞增殖的能力,并且其在表达ITD和TKD突变体FLT3受体或过表达野生型FLT3和PDGF受体的白血病细胞中诱导凋亡。 Midostaurin还表现出抑制KIT信号,细胞增殖和组胺释放并诱导肥大细胞凋亡的能力。 适用范围及用途 RYDAPT是一种激素抑制剂,用于治疗成人患者: 新诊断为FLT3突变阳性的急性骨髓性白血病(AML),通过FDA批准的检测,与标准阿糖胞苷和柔红霉素诱导和阿糖胞苷固定联合检测。 使用限制: RYDAPT未被指定为用于治疗AML患者的单一药物诱导疗法。 侵袭性系统性肥大细胞增多症(ASM),伴有血液肿瘤的系统性肥大细胞增多症(SM-AHN)或肥大细胞白血病(MCL)。 剂量和管理 AML:50毫克口服每日两次食物。 ASM,SM-AHN和MCL:100毫克口服每日两次食物。 剂量形式和强度 胶囊:25mg 禁忌症 对midostaurin或任何赋形剂的超敏反应 警告和注意事项 胚胎 - 胎儿毒性:当对孕妇进行管理时,RYDAPT可能会引起胎儿的伤害。建议胎儿的潜在风险。 肺部毒性:监测间质性肺病或肺炎的症状。停止RYDAPT患有肺部毒性征兆或症状的患者。发生致命案件。 不良反应 AML:最常见的不良反应(≥20%)为发热性中性粒细胞减少症,恶心,粘膜炎,呕吐,头痛,瘀点,肌肉骨骼疼痛,鼻出血,器官相关感染,高血糖症和上呼吸道感染。 ASM,SM-AHN或MCL:最常见的不良反应(≥20%)为恶心,呕吐,腹泻,水肿,肌肉骨骼疼痛,腹痛,疲劳,上呼吸道感染,便秘,发热,头痛和呼吸困难。 药物相互作用 强烈的CYP3A4抑制剂:强CYP3A4抑制剂可能会增加甲磺酸和其活性代谢物的接触。考虑不强烈抑制CYP3A4或监测增加不良反应风险的替代疗法。 强烈的CYP3A4诱导剂:避免伴随使用,因为强烈的CYP3A4诱导剂可降低甲磺酸和其活性代谢物的接触。 在特定人口中使用 哺乳:建议女性不要母乳喂养。
Rydapt (Midostaurin Capsules) RYDAPT Rx Generic Name and Formulations: Midostaurin 25mg; caps. Company: Novartis Pharmaceuticals Corp Select therapeutic use: Leukemias, lymphomas, and other hematologic cancers Indications for RYDAPT: Treatment of adults with newly diagnosed FLT3 mutation-positive acute myeloid leukemia (AML) as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction + cytarabine consolidation. Treatment of adults with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL). Limitations Of use: Not for use as single-agent induction therapy for AML. Adult: Swallow whole. Take with food approx. 12hrs apart. Give prophylactic antiemetics prior to initiation. AML: 50mg twice daily on Days 8–21 of each induction cycle with cytarabine and daunorubicin, and on Days 8–21 of each consolidation cycle with high-dose cytarabine. ASM, SM-AHN, MCL: 100mg twice daily until disease progression or unacceptable toxicity. Dose modifications: see full labeling. Children: Not established. Warnings/Precautions: For ASM, SM-AHN, MCL: Monitor for toxicity at least weekly for first 4 weeks, every other week for next 8 weeks, and monthly thereafter. Discontinue if low ANC, platelet count, or hemoglobin persists >21 days. Interrupt dose if Grade 3/4 nausea and/or vomiting despite antiemetics or other Grade 3/4 non-hematological toxicities; resume at reduced dose and increase if tolerated (see full labeling). Both: monitor for signs/symptoms of interstitial lung disease or pneumonitis; discontinue if pulmonary toxicity develops. Embryo-fetal toxicity. Pregnancy; exclude status within 7 days prior to initiation. Females of reproductive potential and males should use effective contraception during and for at least 4 months after last dose. Nursing mothers: not recommended (during and for at least 4 months after last dose). Interactions: Concomitant drugs that prolong QT interval; monitor EKG periodically. Potentiated by strong CYP3A inhibitors (eg, boceprevir, clarithromycin, cobicistat, conivaptan, danoprevir/ritonavir, diltiazem, elvitegravir/ritonavir, grapefruit juice, idelalisib, indinavir/ritonavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, paritaprevir/ritonavir and [ombitasvir and/or dasabuvir], posaconazole, ritonavir, saquinavir/ritonavir, tipranavir/ritonavir, troleandomycin, voriconazole); consider alternatives; if co-administration needed, monitor for increased adverse reactions. Avoid concomitant strong CYP3A inducers (eg, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's wort). Pharmacological Class: Kinase inhibitor. Adverse Reactions: AML: Febrile neutropenia, nausea, mucositis, vomiting, headache, petechiae, musculoskeletal pain, epistaxis, device-related infection, hyperglycemia, upper respiratory tract infection. ASM, SM-AHN, MCL: also diarrhea, edema, abdominal pain, fatigue, constipation, pyrexia, dyspnea; pulmonary toxicity. Generic Availability: NO How Supplied: Caps—56, 112 ------------------------------------------------------ 产地国家:德国 原产地英文商品名: Rydapt 25mg/capsules 112capsules(4x28)/box 原产地英文药品名: midostaurin 中文参考商品译名: Rydapt 25毫克/胶囊 112胶囊(4x28粒)/盒 中文参考药品译名: 雷德帕斯 生产厂家中文参考译名: 诺华公司 生产厂家英文名: Novartis GmbH 曾用名: 雷德帕思;雷德帕斯
|